1
|
Fang Z, Chen S, Manchanda Y, Bitsi S, Pickford P, David A, Shchepinova MM, Corrêa Jr IR, Hodson DJ, Broichhagen J, Tate EW, Reimann F, Salem V, Rutter GA, Tan T, Bloom SR, Tomas A, Jones B. Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. Int J Mol Sci 2020; 21:E8404. [PMID: 33182425 PMCID: PMC7664906 DOI: 10.3390/ijms21218404] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Revised: 11/01/2020] [Accepted: 11/02/2020] [Indexed: 12/30/2022] Open
Abstract
The glucagon-like peptide-1 receptor (GLP-1R) is an important regulator of blood glucose homeostasis. Ligand-specific differences in membrane trafficking of the GLP-1R influence its signalling properties and therapeutic potential in type 2 diabetes. Here, we have evaluated how different factors combine to control the post-endocytic trafficking of GLP-1R to recycling versus degradative pathways. Experiments were performed in primary islet cells, INS-1 832/3 clonal beta cells and HEK293 cells, using biorthogonal labelling of GLP-1R to determine its localisation and degradation after treatment with GLP-1, exendin-4 and several further GLP-1R agonist peptides. We also characterised the effect of a rare GLP1R coding variant, T149M, and the role of endosomal peptidase endothelin-converting enzyme-1 (ECE-1), in GLP1R trafficking. Our data reveal how treatment with GLP-1 versus exendin-4 is associated with preferential GLP-1R targeting towards a recycling pathway. GLP-1, but not exendin-4, is a substrate for ECE-1, and the resultant propensity to intra-endosomal degradation, in conjunction with differences in binding affinity, contributes to alterations in GLP-1R trafficking behaviours and degradation. The T149M GLP-1R variant shows reduced signalling and internalisation responses, which is likely to be due to disruption of the cytoplasmic region that couples to intracellular effectors. These observations provide insights into how ligand- and genotype-specific factors can influence GLP-1R trafficking.
Collapse
Affiliation(s)
- Zijian Fang
- Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK; (Z.F.); (S.C.); (P.P.); (V.S.); (T.T.); (S.R.B.)
- Wellcome Trust–Medical Research Council Cambridge Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge CB2 0AW, UK
| | - Shiqian Chen
- Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK; (Z.F.); (S.C.); (P.P.); (V.S.); (T.T.); (S.R.B.)
| | - Yusman Manchanda
- Section of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK; (Y.M.); (S.B.); (G.A.R.)
| | - Stavroula Bitsi
- Section of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK; (Y.M.); (S.B.); (G.A.R.)
| | - Philip Pickford
- Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK; (Z.F.); (S.C.); (P.P.); (V.S.); (T.T.); (S.R.B.)
| | - Alessia David
- Centre for Bioinformatics and System Biology, Department of Life Sciences, Imperial College London, London SW7 2BX, UK;
| | - Maria M. Shchepinova
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London W12 0BZ, UK; (M.M.S.); (E.W.T.)
| | | | - David J. Hodson
- Institute of Metabolism and Systems Research (IMSR), and Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham, Birmingham B15 2TT, UK;
- Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham B15 2TT, UK
| | - Johannes Broichhagen
- Department of Chemical Biology, Leibniz-Forschungsinstitut für Molekulare Pharmakologie, 13125 Berlin, Germany;
- Department of Chemical Biology, Max Planck Institute for Medical Research, 69120 Heidelberg, Germany
| | - Edward W. Tate
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 80 Wood Lane, London W12 0BZ, UK; (M.M.S.); (E.W.T.)
| | - Frank Reimann
- Institute of Metabolic Science & MRC Metabolic Diseases Unit, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK;
| | - Victoria Salem
- Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK; (Z.F.); (S.C.); (P.P.); (V.S.); (T.T.); (S.R.B.)
| | - Guy A. Rutter
- Section of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK; (Y.M.); (S.B.); (G.A.R.)
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 639798, Singapore
| | - Tricia Tan
- Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK; (Z.F.); (S.C.); (P.P.); (V.S.); (T.T.); (S.R.B.)
| | - Stephen R. Bloom
- Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK; (Z.F.); (S.C.); (P.P.); (V.S.); (T.T.); (S.R.B.)
| | - Alejandra Tomas
- Section of Cell Biology and Functional Genomics, Imperial College London, London W12 0NN, UK; (Y.M.); (S.B.); (G.A.R.)
| | - Ben Jones
- Section of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK; (Z.F.); (S.C.); (P.P.); (V.S.); (T.T.); (S.R.B.)
| |
Collapse
|